Unfortunately, long term administration of TZB can increase IL-6 levels through onset of CSCs, inducing a serious side effect, CRCC, and decrease anti-cancer efficacy by activating the NF-κB signaling and downstream apoptotic pathways in cancer patients [35, 76]. This evidence concerns the gene IL6 and chromophobe renal cell carcinoma.